DrBicuspid

CEL-SCI extends clinical trials for head/neck cancer drug

Pharmaceutical company CEL-SCI has begun phase III clinical trials for its immunotherapy drug Multikine in Hungary. Studies are already ongoing at 12 clinical sites in the U.S., Canada, Poland, and ...
DrBicuspid

CEL-SCI expands head/neck cancer drug trial

CEL-SCI is expanding its phase III trial of the investigational therapy Multikine to four additional European countries: Spain, the Czech Republic, Slovakia, and Croatia. These countries were selected ...
Seeking Alpha

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics (AUTL) plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the ...
Healthline

Oral Cancer Progression and Outlook

The most common type of oral cancer tends to spread quickly, but progression depends on several factors, including location. Early diagnosis and treatment are key. Oral cancer refers to cancer that ...
Nasdaq

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Session Title: Gene therapy and cellular immunotherapy - ClinicalPresentation ID: S262Session date and time: Saturday, June 10, 2023, 11:00 – 11:15 EDT, 16:00 ...